|
Market Cap (6-Jul) TBC |
Close (30-Jun) $0.059 |
Volume (30-Jun) 4,352,698 |
Shortsold (24-Jul) 256 (0.00%) (719th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS - |
ANP released this announcement to the ASX on 28 July 2022, 9:45. The announcement is not marked as price sensitive, and is 16 page(s) in length and 1.37MB in size.
You can view all announcements from ANP and see how they appear on a price chart on the announcements page.
At the date of this announcement, ANP was 0.003% short sold according to ASIC data. It was ranked the 655th most shorted stock on the ASX. It remains ranked 719th as of the latest reported data (24 July 2023).
| Other Recent Announcements from ANP | |
|---|---|
| MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK | 27 June 2023, 15:46 |
| First Patient Dosed in ATL1102 Phase IIb DMD Trial | 8 June 2023, 8:38 |
| Shareholder Newsletter | 6 June 2023, 15:47 |
| Investor Presentation | 28 July 2022, 9:45 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 27 July 2022, 16:19 |
| ATL1102 DMD Clinical Trial Application Submitted in Europe | 13 July 2022, 9:24 |
| Proteomics and disease marker identification in DMD Webinar | 28 June 2022, 16:57 |
You must be logged in to post a reply.
Antisense Therapeutics 